MX2023000403A - Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip). - Google Patents

Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip).

Info

Publication number
MX2023000403A
MX2023000403A MX2023000403A MX2023000403A MX2023000403A MX 2023000403 A MX2023000403 A MX 2023000403A MX 2023000403 A MX2023000403 A MX 2023000403A MX 2023000403 A MX2023000403 A MX 2023000403A MX 2023000403 A MX2023000403 A MX 2023000403A
Authority
MX
Mexico
Prior art keywords
agonists
glp
gip receptor
gip
obesity
Prior art date
Application number
MX2023000403A
Other languages
English (en)
Inventor
Brian Finan
Patrick J Knerr
Richard Dimarchi
Fa Liu
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2023000403A publication Critical patent/MX2023000403A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen coagonistas peptídicos de los receptores de GLP-1 y GIP humanos, los derivados de acción prolongada de los mismos y sus usos médicos en el tratamiento y/o la prevención de la obesidad, la diabetes y/o enfermedades hepáticas.
MX2023000403A 2020-07-22 2021-07-22 Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip). MX2023000403A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063055063P 2020-07-22 2020-07-22
EP20192415 2020-08-24
PCT/EP2021/070483 WO2022018185A1 (en) 2020-07-22 2021-07-22 Glp-1 and gip receptor co-agonists

Publications (1)

Publication Number Publication Date
MX2023000403A true MX2023000403A (es) 2023-02-02

Family

ID=77179984

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000403A MX2023000403A (es) 2020-07-22 2021-07-22 Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip).

Country Status (14)

Country Link
US (1) US20230346961A1 (es)
EP (1) EP4185606A1 (es)
JP (1) JP2023534130A (es)
KR (1) KR20230042019A (es)
CN (1) CN116157414A (es)
AU (1) AU2021313377A1 (es)
BR (1) BR112023000229A2 (es)
CA (1) CA3184723A1 (es)
CL (1) CL2023000090A1 (es)
CO (1) CO2023000125A2 (es)
IL (1) IL299707A (es)
MX (1) MX2023000403A (es)
TW (1) TW202214679A (es)
WO (1) WO2022018185A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402219A (zh) * 2022-07-13 2024-01-16 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP6108659B2 (ja) 2008-06-17 2017-04-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト
JP2014501762A (ja) * 2010-12-22 2014-01-23 マルケイディア バイオテック， インコーポレイテッド Ｇｉｐおよびｇｌｐ−１受容体活性グルカゴン系ペプチドにより代謝障害および肥満を治療するための方法
EP2718317B1 (en) 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
JP6356660B2 (ja) * 2012-03-22 2018-07-11 ノヴォ ノルディスク アー／エス 送達剤を含む組成物およびその調製
EA028665B1 (ru) 2012-05-03 2017-12-29 Зилэнд Фарма А/С Соединения - двойные агонисты gip-glp-1 и способы
JP2016503771A (ja) 2012-12-21 2016-02-08 サノフイ エキセンジン−４誘導体
MY172578A (en) * 2013-05-02 2019-12-03 Novo Nordisk As Oral dosing of glp-1 compounds
DK3004155T3 (da) 2013-05-28 2022-01-03 Takeda Pharmaceuticals Co Peptidforbindelse
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
MX2016005556A (es) * 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
JOP20210016A1 (ar) 2018-07-23 2021-01-21 Lilly Co Eli مركبات مساعدة مشتركة gip/glp1

Also Published As

Publication number Publication date
JP2023534130A (ja) 2023-08-08
TW202214679A (zh) 2022-04-16
CO2023000125A2 (es) 2023-04-17
CA3184723A1 (en) 2022-01-27
BR112023000229A2 (pt) 2023-01-31
KR20230042019A (ko) 2023-03-27
US20230346961A1 (en) 2023-11-02
AU2021313377A1 (en) 2023-02-02
EP4185606A1 (en) 2023-05-31
IL299707A (en) 2023-03-01
CN116157414A (zh) 2023-05-23
WO2022018185A1 (en) 2022-01-27
CL2023000090A1 (es) 2023-07-07

Similar Documents

Publication Publication Date Title
MX2023000303A (es) Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
CR20210040A (es) Compuestos coagonistas de gip/glp1
CR20230330A (es) Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso
NZ746784A (en) Glucagon and glp-1 co-agonists for the treatment of obesity
PH12020551742A1 (en) Gip derivatives and uses thereof
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
TW200744642A (en) Novel peptides for use in the treatment of obesity
DE60336821D1 (de) Gegen das c5-komponent des komplementsystems gerichtete antikörper und deren verwendung
NO20070614L (no) Humane glukagon-lignende-peptid-1 modulatorer og anvendelse derav ved behandling av diabetes og beslektede tilstander.
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
UA106756C2 (uk) Генетичні маркери, асоційовані з відповіддю на інтерферон-альфа
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
MX2010006388A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina.
MX2021006552A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
MX2021006884A (es) Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina.
BR112017025000A2 (pt) tratamento de hipoglicemia pós-bariátrica com exendina (9-39)
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
MX2023000403A (es) Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del peptido insulinotropico dependiente de glucosa (gip).
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
PH12021551174A1 (en) Novel folr1 specific binding proteins for cancer diagnosis and treatment
MX2019014687A (es) Formulaciones farmaceuticas orales de remogliflozina.
MX2023009550A (es) Antagonistas del receptor del peptido-1 tipo glucagon.
TWI799923B (zh) 硫代咪唑烷酮藥物在治療covid-19疾病中的用途
MX2022014368A (es) Compuesto de agonista doble para receptores de glp-1 y gip y aplicacion del mismo.